» Articles » PMID: 34817507

Comparison of Nonspecific Inflammatory Markers in Endometrial Cancer and Hyperplasia

Overview
Specialty General Medicine
Date 2021 Nov 24
PMID 34817507
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: This study aims to analyze inflammatory markers among patients with endometrial cancer, hyperplasia with atypia/endometrial intraepithelial neoplasia, hyperplasia without atypia, and normal controls, thus observing the stage at which inflammation becomes the most significant.

Methods: A total of 444 patients who had endometrial sampling were included in the study (endometrial cancer, n=79; endometrial hyperplasia with atypia/endometrial intraepithelial neoplasia, n=27; endometrial hyperplasia without atypia, n=238; and normal controls, n=100). Neutrophil count, lymphocyte count, platelet count, platelet distribution width, neutrophil/lymphocyte ratio, platelet/lymphocyte ratio, CA-125, and endometrial thickness of the patients were recorded.

Results: Comparing the groups for neutrophil count, the hyperplasia with atypia group had higher values compared with both the hyperplasia without atypia group and the control group (p=0.003). When compared for the lymphocyte count, the hyperplasia with atypia group had lower values compared with the control group (p=0.014). Neutrophil/lymphocyte ratio of the hyperplasia with atypia group was higher than all other groups, and neutrophil/lymphocyte ratio of the cancer group was higher than the control group (p=0.001). Platelet count, mean platelet volume, platelet distribution width, and platelet/lymphocyte ratio values were not significantly different among groups (p>0.05).

Conclusions: Considering the inflammatory markers, the most prominent result was that the hyperplasia with atypia group had neutrophilia, lymphopenia, and increased neutrophil/lymphocyte ratio compared with other groups.

Citing Articles

Preoperative Haematologic Markers for the Differentiation of Endometrial Cancer from Benign Endometrial Lesions in Postmenopausal Patients with Endometrial Masses.

Song Y, Kim H, Yoon H, Choi K, Suh D, Kim K Cancer Manag Res. 2023; 15:1111-1121.

PMID: 37822733 PMC: 10563776. DOI: 10.2147/CMAR.S430013.


for the treatment of malignant tumors of the female reproductive system: A review of traditional Chinese medicinal uses, phytochemistry, pharmacokinetics, and pharmacodynamics.

Pan X, Shen Q, Zhang C, Zhang X, Li Y, Chang Z Front Pharmacol. 2023; 14:1129874.

PMID: 36909176 PMC: 9995914. DOI: 10.3389/fphar.2023.1129874.